摘要
胶质母细胞瘤是成人最常见且最致命的肿瘤之一,由于其进展迅速、侵袭性强和血脑屏障的存在,胶质母细胞瘤的治疗有别于其他实体肿瘤,常规治疗预后欠佳。使用免疫疗法治疗胶质母细胞瘤的探索已经持续了几十年,效果也欠佳。但随着胶质母细胞瘤特异性抗原的研究进展、各项相关技术的发展以及早期临床试验的成功,免疫疗法又回到了人们的视线中。嵌合抗原受体T细胞(chimeric antigen receptor-modified T cell,CAR-T)治疗是一种新兴的肿瘤免疫疗法。该文回顾既往文献,总结了一些可用于CAR-T疗法治疗胶质母细胞瘤的相关抗原,并总结了CAR-T疗法治疗胶质母细胞瘤在内的实体肿瘤所面临的问题和挑战,包括肿瘤微环境中存在的T细胞耗竭、肿瘤的异质性、归巢率低等,对CAR-T疗法改进方案等进行综述。
Glioblastoma is one of the most common and deadly neoplasms in adults.The rapid progress and strong invasiveness of glioblastoma and the presence of the blood-brain barrier make the treatment of glioblastoma different from other solid tumors and these are the reasons for the poor prognosis of conventional treatment.The exploration of immunotherapy in the treatment of glioblastoma has lasted for decades,but the outcome is not good yet.However,with the research progress of glioblastoma-specific antigen,the development of various related technologies and the success of early clinical trials,it has come back to people's attention.Chimeric antigen receptor-modified T cell(CAR-T)is a new kind of tumor immunotherapy.Reviewing the previous literatures,this article summarizes some related antigens that can be used to CAR-T therapy to treat glioblastoma,the problems and challenges faced by CAR-T therapy in the treatment of glioblastoma and other solid tumors,including T cell depletion in tumor microenvironment,heterogeneity of tumor and low homing rate,and some potential improvements in CAR-T therapy.
作者
那迪娜·帕尔哈提
严妍
车千纪
罗菁
刘鑫男
李斌
NADINA Paerhati;YAN Yan;CHE Qian-ji;LUO Jing;LIU Xin-nan;LI Bin(Shanghai Institute of Immunology,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)
出处
《上海交通大学学报（医学版）》
CAS
CSCD
北大核心
2021年第7期982-986,共5页
Journal of Shanghai Jiao tong University:Medical Science
基金
上海交通大学医学院第十三期大学生创新项目(1319003)。
关键词
嵌合抗原受体T细胞
免疫疗法
胶质母细胞瘤
异质性
肿瘤微环境
chimeric antigen receptor-modified T cell(CAR-T)
immunotherapy
glioblastoma
heterogeneity
tumor microenvironment
